Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...
In the wake of multiple cases of human metapneumovirus (hMPV) in India, multiple questions about its causes and symptoms seem ...
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...
GlobalData on MSN20h
Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trialShionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...
Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.
Virbac is expanding its U.S. cattle range of products with four vaccines — Bovigen Platinum 5, Bovigen Platinum 5 L5, Bovigen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback